Lassa fever countermeasures gather pace

Two early phase clinical trials represent progress in Lassa fever vaccine and therapeutic development, including the first interventional treatment trial in decades. This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout References Garry, R. F. Nat. Rev. Microbiol. 21, 87–96 (2023). Ortiz, J. R. et al. Nat. Med. https://doi.org/10.1038/s41591-026-04429-z (2026). Erameh, C. et al. Nat. Med. https://doi.org/10.1038/s41591-026-04402-w (2026). Malkin, E. et al. N. Engl. J. Med. 393, 1807–1818 (2025). Tschismarov, R. et al. Lancet 401, 1267–1276 (2023). Salam, A. P. et al. PLoS Negl. Trop. Dis. 15, e0009522 (2021). Korula, P. et al. Cochrane Database Syst. Rev. 2, CD015219 (2024). Hayden, F. G. et al. J. Infect. Dis. 226, 1790–1799 (2022). Salam, A. P. et al. PLoS Negl. Trop. Dis. 16, e0010289 (2022). Author information Authors and Affiliations Corresponding author Ethics declarations Competing interests D.J. has previously worked on rabies and Lassa vaccine candidates, but not on the candidates discussed in this piece, and declares no competing financial interests. Rights and permissions About this article Cite this article Jenkin, D. Lassa fever countermeasures gather pace. Nat Med (2026). https://doi.org/10.1038/s41591-026-04478-4 Published: Version of record: DOI: https://doi.org/10.1038/s41591-026-04478-4